The new treatment targets gut hormone GLP-1 but also mimics amylin, a hormone released by the pancreas that suppresses hunger.

Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a gradual loss of kidney function.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies, according to the Prescription Medicines Code of Practice Authority (PMCPA).

The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients with chronic kidney disease,

When Novo Nordisk unveiled kidney outcomes data for its star GLP-1 medicine Ozempic last May, the company’s executive medical director suggested the results could help set a new standard for “holis | The FDA on Tuesday gave Ozempic a thumbs-up to reduce the risk of kidney disease worsening,

Last month, the European Medicines Agency allowed Novo to add risk reduction for events related to kidney disease to the label of Ozempic.

A handout photo shows a nine-month supply of Novo Nordisk's diabetes drug Ozempic which was purchased by an individual from online pharmacies in the UK for "off-label" use for weight loss and stored in his refrigerator at home in London,

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic kidney disease,

Novo Nordisk A/S’s blockbuster Ozempic won US approval to treat chronic kidney disease in patients who also have type 2 diabetes, further expanding the popular drug’s use.